Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04753294
Other study ID # PD-598654
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 14, 2021
Est. completion date July 21, 2023

Study information

Verified date February 2023
Source Molnlycke Health Care AB
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this post market clinical follow-up (PMCF) investigation is to confirm the safety and performance of Avance®Solo and Avance®Solo Adapt NPWT Systems in low to moderate exuding chronic wounds when used in accordance with the Instructions for Use, for up to 28 days.


Description:

This investigation is designed as a prospective, open and non-comparative PMCF investigation to confirm the safety and performance of Avance®Solo and Avance®Solo Adapt in low to moderate exuding chronic wounds. This is a multi-center study that will take place in approximately 5 European countries. The target subjects are male or female, 18 years or older with low to moderate exuding chronic wounds (pressure ulcers (N=68), diabetic foot ulcers (N=34), and venous leg ulcers (N=34)) suitable for NPWT as deemed by the investigator. Two different options of Negative Pressure Wound Therapies (NPWT) will be evaluated through this clinical investigation A total of 136 subjects will receive treatment with the investigational devices within the intended use according to Instructions for Use (IfU): Group 1: 102 subjects in total, 34 subjects per indication (pressure ulcers, diabetic foot ulcers, and venous leg ulcers) treated with Avance®Solo and Group 2: 34 subjects with pressure ulcers treated with Avance®Solo Adapt. Subjects will be managed and monitored for a maximum of 4 weeks or until withdrawal from investigation for any reason. The primary performance endpoint will include assessment of wound progress compared to last visit during a maximum 28 days investigation period. Wound progression is determined by the Investigator and will take into account all aspects of wound characteristics. Wound progression will be assessed by the Investigator at each follow-up visit and measured by three outcomes: - Deteriorated - No change - Improved


Recruitment information / eligibility

Status Completed
Enrollment 136
Est. completion date July 21, 2023
Est. primary completion date July 15, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female = 18 years. 2. Signed written informed consent. 3. Low to moderate exuding chronic wounds (diabetic foot ulcers, venous leg ulcers and pressure ulcers for Avance®Solo or pressure ulcers for Avance®Solo Adapt) suitable for NPWT according to the investigator´s judgement and Instructions for Use. 4. Subjects that will be capable and willing to comply with protocol instructions Exclusion Criteria: 1. Known malignancy in the wound or margins of the wound 2. Untreated and previously confirmed osteomyelitis 3. Non-enteric and unexplored fistulas 4. Necrotic tissue with eschar present 5. Exposed nerves, arteries, veins or organs 6. Exposed anastomotic site 7. Known allergy/hypersensitivity to the dressing or its components. 8. Known pregnancy or planning to become pregnant or lactation at time of study participation. 9. Participation in another investigative drug or device trial currently or within the last 30 days Subjects not suitable for the investigation according to the Investigator's judgement, Clinical Investigation Plan and Instructions for Use

Study Design


Intervention

Device:
Avance Solo NPWT System
Wound treatment with Avance Solo NPWT System for up to 28 days.
Avance Solo Adapt NPWT System
Wound treatment with Avance Solo Adapt NPWT System for up to 28 days.

Locations

Country Name City State
Belgium Diensthoofd wondkliniek, UZ Gent Gent
Belgium AZ Delta Roeselare
Denmark North Zeeland Hospital Hillerød
France CHU Montpellier Montpellier
Germany Franziskus-Krankenhaus Berlin Berlin
Germany Klinik fur Dermatologie, Venerologie und Allergologie Campus Benjamin Franklin Berlin
Germany Klinikum der Ruhr-Universität Bochum Bochum
Ireland St James's Hospital Dublin
Italy Ospedale San Raffaele S.r.I. Milano
Italy A.O.U. Citta della Salute e della Scienza di Torino - A.O.U. Molinette San Giovanni Battista Torino
Portugal Santa casa da Misericórdia de Aveiro Aveiro
Portugal Unidade de Cuidados Continuados António Francisco Guimarães Guimarães
Portugal Trofa Saúde Hospital Central Hospital da Trofa Touguinho

Sponsors (2)

Lead Sponsor Collaborator
Molnlycke Health Care AB Syntactx

Countries where clinical trial is conducted

Belgium,  Denmark,  France,  Germany,  Ireland,  Italy,  Portugal, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in wound progress Wound progress compared to last visit and assessed as:
Deteriorated
No change
Improved
Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Wound progress Wound progress compared between baseline and final visit and assessed as:
Deteriorated
No change
Improved
28 days
Secondary Absolute change in wound area Absolute change in wound area from baseline to all follow-up visits Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Absolute change in wound volume Absolute change in wound volume from baseline to all follow-up visits Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Percentage change in wound area Percentage change in wound area from baseline to all follow-up visits Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Percentage change in wound volume Percentage change in wound volume from baseline to all follow-up visits Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Tissue type Change in tissue type (slough, necrotic, granulation or epithelization) from baseline to all follow-up visits. Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Exudate amount Change in exudate amount using a category scoring system from baseline to all follow-up visits.
Amount: none, low, moderate, or high)
Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Exudate nature Change in exudate nature using a category scoring system from baseline to all follow-up visits.
Nature: serous, fibrinous, serosanguineous, sanguineous, seropurulent, purulent, foul purulent, heamopurulent, or hemorrhagic
Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Exudate odor Change in exudate odor using a category scoring system from baseline to all follow-up visits.
Odor: no odor, slight, moderate, strong, and very strong
Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Peri-wound Change in peri-wound skin condition from baseline to all follow-up visits using the following conditions:
Normal
Erythematous
Oedematous
Eczematous
Excoriated
Macerated
Indurated
Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Tissue in-growth Degree of tissue in-growth when Avance Solo foam is utilized at all follow-up visits as well as extra visits. Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days) with additional assessments in between when dressing is changed
Secondary Pain assessment Subject evaluation of pain at Avance Solo dressing or Avance Solo Adapt Film removal using Numeric Rating Scale (NRS) at each follow-up visit. Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Trauma Proportion of subjects with trauma to the wound site and surrounding skin for Avance Solo Border Dressing, fixation strips or Avance Solo Adapt Film at all follow-up visits. Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Quality of life assessed using Numeric Rating Scale (NRS) Impact of everyday life by the systems will be captured through a NRS scale where the subject grade how much the treatment has affected the subject's daily life. 0 is equal to no influence and 10 to considerable influence on everyday life or unbearable.
If replying >0, the subject will state the presence or absence of the following causes:
Leakage of dressing
Impaired mobility
Difficulties in getting dressed
Pain
Odor
28 days
Secondary Alarms Subject evaluation of the system properties (number of sounding alarms) assessed with a given scale at all follow-up visits
0
1-5
6-10
11-15
16-20
More than 20
Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Compliance Evaluate the compliance to the provided therapy by average number of hours per 24h that the system has not provided treatment since last visit. Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Ability to absorb and/or transport exudate via clinical judgement Evaluation of the Systems ability to absorb and/or transport exudate assessed using a rating scale by the clinician/designee:
Very Poor
Poor
Good
Very Good
Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Ease of application Clinician evaluation of ease of application and removal of Avance®Solo or Avance®Solo Adapt using a Numeric Rating Scale (NRS) collected at baseline, and each follow-up visit. Baseline, Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Global satisfaction Evaluate the investigator and subject global satisfaction of the systems in regards to:
Very dissatisfied
Dissatisfied
Neither satisfied or dissatisfied
Satisfied
Very satisfied
28 days
Secondary Product consumption Product consumption of the utilized products for the system's, from baseline and final visit using the Avance Solo or Avance Solo Adapt NPWT System Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
Secondary Wear time Evaluate Avance®Solo or Avance®Solo Adapt wear time in days from baseline to all follow-up visits including potential extra visits Day 7 (+0/-2 days), Day 14 (+0/-2 days), Day 21 (+0/-2 days), and Day 28 (+0/-2 days)
See also
  Status Clinical Trial Phase
Recruiting NCT04497805 - Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers Phase 2
Withdrawn NCT03675269 - Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer: N/A
Completed NCT04624516 - Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence N/A
Not yet recruiting NCT06439667 - VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
Recruiting NCT05608187 - Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers Phase 2
Not yet recruiting NCT06278935 - Lifestyle Tailored Offloading for Diabetic Foot Ulcers N/A
Not yet recruiting NCT06437028 - Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers. N/A
Withdrawn NCT05024656 - AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers N/A
Terminated NCT02202668 - Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers N/A
Completed NCT01951768 - Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Phase 4
Terminated NCT01966380 - Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia Phase 2
Completed NCT01657474 - Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers N/A
Active, not recruiting NCT00389636 - TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers N/A
Completed NCT01181440 - Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers Phase 3
Enrolling by invitation NCT05888259 - Plantar Pressure Distribution in Diabetic Foot Ulcer N/A
Completed NCT04054804 - Digital Foot Check by Using the D-Foot, a New Software
Not yet recruiting NCT05877378 - Efficacy of PICO Single-use System in Chronic Ulcers N/A
Recruiting NCT06037369 - The Short Message-based Customized Standardized N/A
Completed NCT03312595 - Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU) N/A
Recruiting NCT04564443 - A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot N/A